BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32074729)

  • 1. [Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis].
    Man J; Chen L; Zhai XW; Ma YY; Wang HS; Qian XW; Feng JY; Zhao J; Cao P; Lu FJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):156-161. PubMed ID: 32074729
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 3. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
    Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
    BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
    Sýkorová A; Procházka V; Móciková H; Janíková A; Pytlík R; Belada D; Benešová K; Klener P; Ďuraš J; Smolej L; Campr V; Blahovcová P; Trněný M
    Neoplasma; 2022 Dec; 69(6):1466-1473. PubMed ID: 36591807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Features and Prognosis of 35 Children with Burkitt Lymphoma/Leukemia].
    Zheng YZ; LE SH; Zheng H; Hua XL; Chen ZS; Zheng L; Chen C; Li M; Cai CX; Yang JH; Chen YQ; Gao QL; Chen YY; Li J; Hu JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1123-1130. PubMed ID: 31418367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China: A Retrospective Single-Center Study.
    Liu R; Zhao H; Xiao G; Tao Y; Tang X; Feng L; Liao B; Liu B; Guan J; Li L; Chen Z; He H; You H
    Technol Cancer Res Treat; 2024; 23():15330338231214236. PubMed ID: 38179657
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases.
    Hong JY; Hong ME; Choi MK; Kim YS; Chang W; Maeng CH; Park S; Lee SJ; Do IG; Jo JS; Jung SH; Kim SJ; Ko YH; Kim WS
    Ann Oncol; 2014 Jan; 25(1):182-8. PubMed ID: 24356628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal dosage of rituximab for children with Burkitt lymphoma.
    Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
    Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the Clinicopathological Characteristics, Treatment and Prognosis of Unclassifiable B-Cell Lymphoma Intermediated between DLCBL and BL].
    Liu DL; Wang B; Zhu YD; Yan F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):443-448. PubMed ID: 29665913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical analysis of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma].
    Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):633-638. PubMed ID: 31495128
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
    Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
    Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
    [No Abstract]   [Full Text] [Related]  

  • 13. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.
    Sang W; Tu D; Zhang M; Qin Y; Yin W; Song X; Sun C; Yan D; Wang X; Zeng L; Li Z; Xu K; Xu L
    J Biochem Mol Toxicol; 2022 Aug; 36(8):e23117. PubMed ID: 35757978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and prognostic analysis of 186 children with Burkitt's lymphoma].
    Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
    Zhonghua Er Ke Za Zhi; 2018 Aug; 56(8):605-610. PubMed ID: 30078243
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical analysis of 60 children with anaplastic large cell lymphoma in a single center].
    Wang M; Mi Q; Yuan Q; Han YL; Wang JM; Luo CY; Pan C; Tang JY; Gao YJ
    Zhonghua Er Ke Za Zhi; 2021 Oct; 59(10):824-829. PubMed ID: 34587677
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
    Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
    [No Abstract]   [Full Text] [Related]  

  • 17. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
    Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
    Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
    Evens AM; Danilov A; Jagadeesh D; Sperling A; Kim SH; Vaca R; Wei C; Rector D; Sundaram S; Reddy N; Lin Y; Farooq U; D'Angelo C; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Yazdy M; Rabinovich E; Varma G; Karmali R; Mian A; Savani M; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein AK; Blum KA; Boughan KM; Smith SE; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Ramdial J; Maliske SM; Epperla N; Venugopal P; Feldman TA; Smith SD; Stadnik A; David KA; Naik S; Lossos IS; Lunning MA; Caimi P; Kamdar M; Palmisiano N; Bachanova V; Portell CA; Phillips T; Olszewski AJ; Alderuccio JP
    Blood; 2021 Jan; 137(3):374-386. PubMed ID: 32663292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
    Wen J; Zhou J; Liu Z; Liu T; Xu C
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.